Nasrallah S M, Tommaso C L, Singleton R T, Backhaus E A
South Med J. 1985 Mar;78(3):312-5. doi: 10.1097/00007611-198503000-00019.
The effect of nifedipine on esophageal symptoms was evaluated in 20 patients with primary esophageal motor disorders. The patients were randomized to receive nifedipine (10 mg t.i.d.) or placebo for two weeks, and then crossed over to receive the other medication. Ten patients had hypertensive lower esophageal sphincter, four had diffuse esophageal spasm, three had vigorous achalasia, two had "nutcracker esophagus," and one patient had achalasia. The score of chest pain or dysphagia was recorded on a scale of 0 to 10 during each study. The patients who received nifedipine improved significantly compared to those who received placebo. This improvement was most marked in patients with hypertensive lower esophageal sphincter. No significant side effects or changes in blood pressure were encountered in any of the study groups. Our results indicate that patients with primary esophageal motor disorders have a good clinical response to nifedipine therapy.
在20例原发性食管运动障碍患者中评估了硝苯地平对食管症状的影响。患者被随机分为两组，一组接受硝苯地平（10毫克，每日三次），另一组接受安慰剂，为期两周，然后交叉接受另一种药物治疗。10例患者有高血压性食管下括约肌，4例有弥漫性食管痉挛，3例有强力性贲门失弛缓症，2例有“胡桃夹食管”，1例有贲门失弛缓症。在每项研究期间，胸痛或吞咽困难的评分以0至10分记录。与接受安慰剂的患者相比，接受硝苯地平的患者有显著改善。这种改善在高血压性食管下括约肌患者中最为明显。在任何研究组中均未出现明显的副作用或血压变化。我们的结果表明，原发性食管运动障碍患者对硝苯地平治疗有良好的临床反应。
